#1HYPERFINE Corporate presentation Hyperfine + Liminal + HealthCor Catalio July 2021 O2021 Hyperfine, Inc. 18000 200kg/440lb MAX#2Disclaimer This presentation is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination ("Business Combination") by and among Health Cor Catalio Acquisition Corp. ("Health Cor Catalio" or the "Company"), Hyperfine, Inc. ("Hyperfine") and Liminal Sciences, Inc. ("Liminal"). The information contained herein does not purport to be all-inclusive and none of Health Cor Catalio, Hyperfine or Liminal, or any of their respective affiliates, or any of their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation. It is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. You should not construe the contents of this presentation as investment, legal, business or tax advice. You should consult with your own counsel, financial advisor and tax advisor as to legal, business, financial, tax and related matters concerning the matters described herein. Important Information about the Business Combination and Where to Find It In connection with the Business Combination, the Company intends to file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "Registration Statement"), which will include a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus, and certain other related documents, which will be both the proxy statement to be distributed to holders of the Company's ordinary shares in connection with the Company's solicitation of proxies for the vote by the Company's shareholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of the Company to be issued in the Business Combination. The Company's shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus included in the Registration Statement and the amendments thereto and the definitive proxy statement/prospectus, as well as other documents filed with the SEC in connection with the Business Combination, as these materials will contain important information about the parties to the Business Combination Agreement (the "Business Combination Agreement"), the Company and the Business Combination. After the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials for the Business Combination will be mailed to shareholders of the Company as of a record date to be established for voting on the Business Combination and other matters as may be described in the Registration Statement. Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's web site at www.sec.gov. In addition, the documents filed by Health Cor Catalio may be obtained free of charge from HealthCor Catalio's website at www.hcspac.com or by written request to Health Cor Catalio at [email protected]. Participants in the Solicitation The Company and its directors and executive officers may be deemed participants in the solicitation of proxies from the Company's shareholders with respect to the Business Combination. You can find information about the Company's directors and executive officers and their ownership of the Company's securities in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 29, 2021, and is available free of charge at the SEC's web site at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Registration Statement when available. Hyperfine, Liminal and their respective directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination will be contained in the Registration Statement when available. © 2021 Hyperfine, Inc. 2A HYPERFINE#3Disclaimer (cont.) Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company's, Hyperfine's and Liminal's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's, Hyperfine's and Liminal's expectations with respect to future performance, development and commercialization of products and services, potential regulatory approvals, and anticipated financial impacts and other effects of the Business Combination, and the size and potential growth of current or future markets for, and the potential benefits of, Hyperfine's, Liminal's and the combined company's products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company's, Hyperfine's and Liminal's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the ability of the Company, Hyperfine and Liminal to meet the closing conditions in the Business Combination Agreement, including due to failure to obtain approval of the shareholders of the Company, Hyperfine and Liminal or certain regulatory approvals, or failure to satisfy other conditions to closing in the Business Combination Agreement; (2) the occurrence of event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against the Company, Hyperfine or Liminal following the announcement of the Business Combination Agreement and the transactions contemplated therein, that could give rise to the termination of the Business Combination Agreement or could otherwise cause the transactions contemplated therein to fail to close; (3) the inability to obtain or maintain the listing of the combined company's Class A common stock on the Nasdaq Capital Market, as applicable, following the Business Combination; (4) the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; (5) the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition and the ability of the combined company to grow and manage growth profitably and retain its key employees; (6) costs related to the Business Combination; (7) changes in applicable laws or regulations; (8) the inability of the combined company to raise financing in the future; (9) the success, cost and timing of Hyperfine's, Liminal's and the combined company's product development activities; (10) the inability of Hyperfine, Liminal or the combined company to obtain and maintain regulatory clearance or approval for their products, and any related restrictions and limitations of any cleared or approved product; (11) the inability of Hyperfine, Liminal or the combined company to identify, in-license or acquire additional technology; (12) the inability of Hyperfine, Liminal or the combined company to maintain Hyperfine's or Liminal's existing or future license, manufacturing, supply and distribution agreements; (13) the inability of Hyperfine, Liminal or the combined company to compete with other companies currently marketing or engaged in the development of products and services that Hyperfine or Liminal is currently marketing or developing; (14) the size and growth potential of the markets for Hyperfine's, Liminal's and the combined company's products and services, and each of their ability to serve those markets, either alone or in partnership with others; (15) the pricing of Hyperfine's, Liminal's and the combined company's products and services and reimbursement for medical procedures conducted using Hyperfine's, Liminal's and the combined company's products and services; (16) Hyperfine's, Liminal's and the combined company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; (17) Hyperfine's, Liminal's and the combined company's financial performance; (18) the impact of COVID-19 on Hyperfine's and Liminal's businesses and/or the ability of the parties to complete the Business Combination; and (19) other risks and uncertainties indicated from time to time in the proxy statement/prospectus relating to the Business Combination, including those under "Risk Factors" in the Registration Statement, and in the Company's other filings with the SEC. The Company, Hyperfine and Liminal caution that the foregoing list of factors is not exclusive. The Company, Hyperfine and Liminal caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company, Hyperfine and Liminal do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based. No Offer or Solicitation This presentation shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. Industry and Market Data This presentation includes information and statistics regarding market participants in the sectors in which Hyperfine or Liminal compete and other industry data which was obtained from third-party sources, including reports by market research firms and company filings. None of the information provided by the third-party sources has been independently verified. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Intellectual Property This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners and are incorporated for illustrative purposes only. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation be listed without the TM, SM, C or R symbols. The Company, Hyperfine and Liminal do not intend the use or display of the trademarks, service marks, trade names or copyrights of such other companies herein to imply a relationship with, or endorsement or sponsorship of the Company, Hyperfine or Liminal by, these other companies. © 2021 Hyperfine, Inc. 2B HYPERFINE#4Seasoned management team with history driving platform and application usage Jonathan Rothberg Dr. Rothberg is the founder and chairman of each 4Catalyzer company, which have together raised over $2B across eight-life science and medical device companies. Jonathan's mission is to build technologies that save lives and maximize societal impact. 0€ 4CATALYZER QuantumSi © 2021 Hyperfine, Inc. Butterfly 454 SEQUENCING ion torrent *AOX+ Chris Gaulin Chris is a Portfolio Manager of Health Cor. He was a health care Portfolio Manager at Soros Fund Management, health care Sector Lead at Maverick Capital, and Senior Analyst at JP Morgan. HealthCor Maverick SOROS Soros Fund Management J.P.Morgan 3 Scott Huennekens Scott is a successful executive, entrepreneur, board member and investor in medical devices having been the startup CEO of two "unicorns" and a part of 10+ startups or growth companies with market valuations that have totaled over $6B. ACUTUS MEDICAL Envista VOLCANO VERB SURGICAL Digirad Dave Scott Dave is a seasoned executive, entrepreneur and was the COO for Verb Surgical. He has more than 25 years of experience building and leading high-performing teams at start-ups and Fortune 500 companies related to surgical robotics, medical imaging and diagnostics. Johnson Johnson Google VERB SURGICAL Abbott INTUITIVE HYPERFINE#5HealthCor Catalio Acquisition Corp (Nasdaq: HCAQ) Health Cor ● ● Health Cor ($3 billion AUM) founded in 2005 by Joseph Healey and Arthur Cohen Partners all have 20+ years investing experience across numerous healthcare cycles 10 person investment team with an average of 12 years of investing in the healthcare sector Extensive Medtech product experience driving large percentage of historical attribution H Health Cor CATALIO CAPITAL MANAGEMENT Completed $207 million SPAC IPO in January 2021. Deal 9x over-subscribed without warrant coverage Experienced SPAC BOD: Mike Weinstein, Taylor Harris, Kenan Turnacioglu and Dr. Chris Wolfgang Catalio founded by G. Petrocheilos and J. Vogelstein. GP consists of world-renowned scientist-entrepreneurs as well as Coatue Manageme Duquesne & Alan Howard © 2021 Hyperfine, Inc. 4 Joseph Healey Health Cor Founder and SPAC Chairman Founding partner and Portfolio Manager at Health Cor with 25+ year investing experience. Prior PM at Kingdon Capital Chris Gaulin Health Cor Partner and SPAC CEO Partner and Portfolio Manager at HealthCor with 20+ year investing experience. Prior PM at Soros Fund Management and Maverick Capital Charlie Nettleton Health Cor Senior Analyst Medical Technology Sector Head at Health Cor with ~ 15 years investing experience. Prior Healthcare banker at JPMorgan HYPERFINE#6Highly compelling investment characteristics. Large Market Poised for Disruption Recurring Revenue Business Model Massive Pipeline Opportunity Hyperfine Capitalized to Succeed Attractive Valuation Relative to Growth Massive TAM of over $23 billion for imaging with potential to take market share and expand the market category. Both companies could unlock huge markets individually but combined have the potential to build an ecosystem across the care continuum. Designed to be a recurring revenue business with annual recurring revenue of greater than $250MM projected by 2025 Product and applications pipeline has the potential to unlock markets with $50 billion in incremental addressable markets for sensing and guided intervention. Liminal Sciences has the potential to substantially change the way neuro care is delivered by providing non-invasive, real-time brain vitals to doctors that were previously inaccessible. ~$375MM¹ of cash to drive Hyperfine through its investment phase and to positive cash flow 10.7x 2023E revenues with projected revenue CAGR of 238% 2021 - 2025 versus comparables² at ~13 - 18x 2023E revenues with meaningfully slower growth CAGRs of ~30%+ © 2021 Hyperfine, Inc. 1: Assuming no redemptions. Comprised of $207.0 million from the SPAC trust fund, $126.1 million from PIPE investors and $65.8 million from Hyperfine/Liminal balance sheet (assumed cash on Hyperfine/Liminal balance sheet at closing of the transaction), less $24.2 million transaction expenses. 2: Based on company projections, public filings, analyst estimates and Capital IQ as of 07/06/21. 5 HYPERFINE#7Transaction overview Sources, uses and pro forma ownership Sources of Funds ($M) Cash in Trust¹ Target Shareholders Equity Rollover Private Placement Target Cash² Sponsor Founder Shares Total Sources Pro Forma Valuation ($M)5 Illustrative Share Price Fully Diluted Shares Outstanding (M)4 Equity Value + Debt - Cash Enterprise Value 2023 Revenue 2023 Revenue Multiple $207.0 $564.8 $126.1 $66.0 $57.9 $1,021.8 $10.00 95.6 $956.0 $0.06 $374.7 $581.3 $54.2 10.7x Uses of Funds ($M) Equity Issued to Target Shareholders Cash to Balance Sheet³ Estimated Transaction Costs Sponsor Founder Shares Payment of Loan Payable Total Uses Pro Forma Valuation5 HealthCor Catalio Founder Shares 6.0% PIPE Investor Shares 13.2% Health Cor Catalio Public Shares 21.7% 6.0% 13.2% 21.7% 48.0% 11.1% $564.8 $374.7 $24.2 $57.9 $0.2 $1,021.8 Hyperfine Equity Rollover 48.0% Liminal Equity Rollover 11.1% 6 © 2021 Hyperfine, Inc. 1: Assumes no redemptions. 2: Assumed cash on Hyperfine/Liminal balance sheet at closing of the transaction. 3: Comprised of $207.0 million from the SPAC trust fund, $126.1 million from PIPE investors and $65.8 million from Hyperfine/Liminal balance sheet (assumed cash on Hyperfine/Liminal balance sheet at closing of the transaction), less $24.2 million transaction expenses. 4: Estimated fully diluted shares outstanding based on (i) Hyperfine shares (45.9M); (ii) Liminal shares (10.6M); (iii) PIPE shares (12.6M); (iv) Health Cor Catalio public shares (20.7M); (v) Health Cor Catalio Sponsor shares (5.8M) 5: Valuation excludes any impact from potential earnouts 6: Reflects estimated debt balance following the closing of the transaction HYPERFINE#8Valuation benchmarking Merger price set at a discount to similar high growth and disruptive companies to incentivize current and new stakeholders to maximize impact High Growth Med-Tech Disruptive Technologies Butterfly INARI Inspire pulmonX SHOCKWAVE SILKROAD> MEDICAL 10x GENOMICS AbCellera biotechnologies HYPERFINE © 2021 Hyperfine, Inc. Source: Based on Capital IQ, public filings and analyst estimates (Butterfly valuation from company estimates) as of 07/06/21 BERKELEY LIGHTS 7 GUARDANT Median EV/ Revenue 2023E 12.7x 17.9x 10.7x Revenue CAGR 2021-2023E 37.9% 33.7% 384.4% HYPERFINE#9Hyperfine Opportunity E 08 matachana HYPERFINE#10© 2021 Hyperfine, Inc. 66 The best way to predict the future is to make it" Jonathan M. Rothberg Vice Chairman and Founder Our mission: To provide affordable and accessible imaging, sensing, and guided robotic intervention to revolutionize healthcare for people around the world. Hyperfine is the third company to go public from the 4C family HYPERFINE 9 Butterfly™ QuantumSi HYPERFINE#11The Hyperfine ecosystem Democratizing Imaging, Sensing and Guided Intervention to cover the care continuum Image (FDA cleared) Intervene (in development) © 2021 Hyperfine, Inc. HYPERFINE 10 8p Sense (in development) A full ecosystem solution: Hardware, software, consumables and applications powered by artificial intelligence HYPERFINE#12Hyperfine has created the next generation of MRI 10 2021 Hyperfine, Inc. MRI 1.0 1980 MAGNETOM Avainto SIEMENS MRI 2.0 1990 11 10000 AAOOOGE HYPERFINE MRI 3.0 FDA Cleared 2020 HYPERFINE#13Hyperfine has created the next generation of MRI MRI 3.0 - FDA Cleared 2020 Patent protected noise cancellation system enables clinical-grade images Portable low-field MRI FDA Cleared 2020 BJ Reimbursed under existing imaging codes © 2021 Hyperfine, Inc. X O co 10000 CAL- HYPERFINE 12 TUDU UUU Current installed base of 46 units Current primary clinical uses: Stroke - Hydrocephalus Cerebral Trauma Acute Mental Status Change HYPERFINE#14Estimated $70+ billion opportunity across the ecosystem PA Imaging Hospitals, Outpatient >100,000 Potential installation targets © 2021 Hyperfine, Inc. $22B $23B 13 $28B Ⓡ Sensing ICUS, Expanded Hospital, Surgical Centers, Outpatient, At-home ~4M Potential unit sales AHE JUU Guided Intervention Hospitals and Health Systems >50M Potential image guided procedures HYPERFINE#15© 2021 Hyperfine, Inc. TRI Adverse events occur in 22-46% of cases during transport 14 Numerous challenges with traditional MRI today High cost limits accessibility Complex site requirements and upgrades Scheduling delays lead to longer length of stay Consumption of valuable personnel resources Risk of adverse events during transportation Maintaining connection to life support equipment TODO E 000 HYPERFINE#16Workflow benefits 2003 MAX&ACCOS © 2021 Hyperfine, Inc. Traditional MRI workflow (25.8 hours) MRI ordered T Patient preparation MRI ordered Intra-hospital transfer to MRI MRI examination Hyperfine workflow (90mins, 94% reduction in total workflow time) 15 MRI examination Post MRI examination Intra-hospital transfer to unit 2021 Post MRI examination HYPERFINE#17Hyperfine addresses challenges of traditional MRI by bringing MRI to the patient C OFF PERFINE ****** Emergency Department © 2021 Hyperfine, Inc. 808 matachara HYPERFINE Intensive Care Units and Operating Rooms Safer and easier to use resulting in a faster time to diagnosis and treatment 16 8800 AACOO # HYPERFINE Global Health HYPERFINE#18Hyperfine portable MRI clinical use cases with current platform (V1) Intensive Care Unit - Acute Mental Status Change - Ataxia - Cerebral Edema - Cerebrovascular Disease - Cranial Neuropathy - Extra Ventricular Drain Placement - Follow-up Intracranial Hemorrhage - Follow-up Ischemic Stroke - Follow-up Hematoma - Stroke - Tumor Pre- and Post-Op Emergency Department - Blurred Vision - Cranial Neuropathy - Dizziness - Headache Numbness - Stroke - Tingling - Traumatic Brain Injury - Vertigo - Weakness © 2021 Hyperfine, Inc. b³ ਦੀ 果 Q 17 TO00 UUU Rehabilitation Clinic - Acute Mental Status Change - Brain Injury After Fall - Stroke Recovery Outpatient Atrophy Monitoring - - Hydrocephalus (Shunt Check) - Multiple Sclerosis Pediatric - Brain Volumetrics - Hypoxic Ischemic Encephalopathy - Hydrocephalus (Dx and Monitoring) - Sports Injury - Suspected Abuse HYPERFINE#19Hyperfine provides compelling platform for stroke diagnosis 15 million people worldwide suffer a stroke annually 88 87% strokes are ischemic strokes Stroke is the 2nd leading cause of death globally © 2021 Hyperfine, Inc. MRI scans are better at detecting ischemic stroke damage compared to CT scans O MRI use for stroke has been limited due to lack of access to this expensive equipment and experienced neuroradiologists to interpret the results. 18 Hyperfine offers an affordable MRI platform that can perform diffusion imaging for stroke diagnosis at the patient's bedside, images can be shared securely with neuroradiologists around the world 10000 (+ HYPERFINE HYPERFINE#20Stroke diagnosis confirmed 62 year old male Presented with new left sided weakness and tremor © 2021 Hyperfine, Inc. Home 142 OSTY M MCA Pal Spacing 181 Thickness: 5.00 W30 L310 0624 M MICA In IMAGE# 10 Markup 38008 L31954 Flip + Rotate POC MAI 06-Jan-2021 14:05:43 Export M Hanging Protocol 19 POM FLAIR 07147 Y MICA FLUID ATTENUATED T80T400000 10000MAGE # 108 GOMAT SERIES #R 08-Jan-2021 Paling 1.0 YALE NEW HAVEN HOSPITAL SOL POCN-42 DWI 142 MICA infart DWI DIFFUSION TE: 72 TL 750.00 TE-100.00 INAGE # 1/30 Jan-2009 Plaal Spacing 14:18:14 Thick$.00 YPERFINE T2 13 Wight F (Lang) RESEARCH ONLY 212220000000 GODT 1429 34 YALE NEW HAVEN HOSPITAL ADC UNKNOWN TE: 030 T: 200.000.00 1418-24 WALE NEW HAVEN HOSPITAL HYPERFINE#21Clinical validation of Hyperfine 66 66 66 Game changer is a good way to put it [...] being able to do the level of sophisticated imaging in an ICU that MRI can provide." UIC Dr. Fady Charbel, MD, FAANS, FACS Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and to make a decision based on the information that's in front of me." Dr. Shahid Nimjee, MD, PhD, FAANS, FAHA OHIOSTATE Portable MRI should be used to image any patients in ICUS in any [clinical] setting." Dr. Michael Schulder, MD, FAANS © 2021 Hyperfine, Inc. Northwell Health Over 25 conference presentations and publications discussing clinical benefits for Stroke | Hydrocephalus | Hematoma | Multiple sclerosis | Tumor resection 20 JAMA Neurology | Original Investigation Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients Kevin N. Sheth, MD; Mercy H. Mazurek, BS; Matthew M. Yuen, BA; Bradley A. Cahn, BS; Jill T. Shah, BA; Adrienne Ward, RN; Jennifer A. Kim, MD, PhD; Emily J. Gilmore, MD; Guido J. Falcone, MD, SCD, MPH; Nils Petersen, MD, PhD; Kevin T. Gobeske, MD, PhD, MPH; Firas Kaddouh, MD; David Y. Hwang, MD; Joseph Schindler, MD; Lauren Sansing, MD, MS; Charles Matouk, MD; Jonathan Rothberg, PhD; Gordon Sze, MD; Jonathan Siner, MD; Matthew S. Rosen, PhD; Serena Spudich, MD, MA; W. Taylor Kimberly, MD, PhD C Large left middle cerebral artery POC T2W POC FLAIR POC T1W DRight anterior cerebral artery and middle cerebral artery watershed infarctions POC T2W POC FLAIR POC T1W POC DWI POC DWI SOC SOC O HYPERFINE#22Hyperfine business model allows for potential widespread adoption © 2021 Hyperfine, Inc. Subscription Model $7,250/month Over $261,000 - 3 year contract value Potential robust recurring revenue stream Software as a Service model could drive significant gross margin 21 Subscription service includes: 4 contrast sequences (T1, T2, FLAIR, DWI with accompanying ADC map) Unlimited service and maintenance Unlimited user training Hyperfine Cloud PACS with unlimited Cloud archive Direct delivery to customer HYPERFINE#23Estimated Hyperfine economic benefits. Financial Benefits analysis based on data from Large Academic Medical Center Cost ED Length of stay and costs Hospital LOS and Costs Transport risks and costs Annual Total Cost Savings Annual Hyperfine Cost Net Annual Cost Savings Incremental MRI revenue Net Annual Savings+Revenue © 2021 Hyperfine, Inc. Amount Saved $115,000 $49,000 $120,000 $284,000 $65,000 $219,000 $57,000 $276,000 22 10000 (+ HYPERFINE HYPERFINE#24இ JIL Pipeline Opportunity HYPERFINE#25Innovative R&D engine designed to expand product roadmap Potential benefits: Location Improved usability $ Lower cost of goods © 2021 Hyperfine, Inc. Expanded Addressable Market Automated Stroke Detection HYPERFINE 24 $1 CEN Stroke C-spine Existing applications V1 Hydrocephalus Extremities Potential future applications V2 Intra and Post Operative HYPERFINE#26Liminal will democratize brain sensing Heart monitors are easy, accurate, and universal After an accident Before and during surgery 11111 At a checkup 2021 Hyperfine, Inc. While exercising 25 8 B ...but access to brain monitors is restricted. A HYPERFINE#27Liminal non-invasive brain vital sensor Breakthrough AEG Technology designed to unlock access to blood flow and pressure © 2021 Hyperfine, Inc. Avg ICP 6 mmHg Avg CBFV 35 cm/s 26 Ows Conhely and Sa Mode Liminal Sciences AEG Smart Bears Steering Audio for Brain Beating Sound Ø m 13 Non-Invasive Risk-free use on every patient to enable broader access and earlier diagnosis Continuous Trend Analysis Continuous sensing to build trends for data-backed treatment Easy to use Designed to be easy to use for immediate, precise care HYPERFINE#28Brain-sensing clinical opportunities © 2021 Hyperfine, Inc. von { d Intensive Care Unit JODO gy Operating Room Outpatient & At Home Emergency Department - Hydrocephalus - Vasospasm - Stroke - Cerebral edema Intraoperative monitoring/anesthesia - Shunts - Epilepsy - Tumor progression - Traumatic Brain Injury - Stroke - Seizures 27 - Traumatic Brain Injury - Subarachnoid hemorrhage - Suspected seizures Acute liver failure Post surgical monitoring - Thrombectomy - Concussion long-term effects - Idiopathic intracranial hypertension Asymptomatic carotid stenosis - Triage for lumbar punctures Altered mental status - Headaches Altered mental status - Brain tumors - Sepsis Hematoma Stent thrombosis - Hypertension - Obstructive sleep apnea - Sickle cell anemia Status epilepticus - Cardiac arrest - Hypertensive urgency and emergency HYPERFINE#29Hyperfine's goal is to build an ecosystem across the care continuum Powered by artificial intelligence Hyperfine aims to provide affordable care at the patient's side... © 2021 Hyperfine, Inc. 8MM Sense fardig ERFINE AAQQOS Image 28 Precision when and where it matters 0.0 HYPERFINE Intervene HYPERFINE#30Future product roadmap To expand from imaging to guided intervention HYPERFINE V2 MRI Imaging neuro, c-spine, extremities and interventional procedures © 2021 Hyperfine, Inc. 2023 Brain Sensing Non-invasively monitor brain vitals for blood flow and pressure HYPERFINE Guided Intervention Image-guided interventions with real-time registration for surgical navigation 29 Guided Intervention Guided Robotics MRI-guided robotics to improve accuracy for life saving interventions HYPERFINE Breast MRI Breast screenings as a safer alternative to detect cancer HYPERFINE#31% $ Financial Overview HYPERFINE#32Install base growth has potential to drive strong revenue and margin profile 5-year revenue projection $ in millions 350.0 300.0 250.0 200.0 150.0 100.0 50.0 0.0 Gross Margin $2.3¹ $16.3 2021E 2022E ■Imaging ■Sensing NM 47.9% $54.2 2023E Interventional 66.0% $141.1 2024E Total Revenue 70.6% $301.6 2025E 71.9% Imaging install base 3,000 2,000 1,000 3,000 2,000 45 1,000 2021E Sensing install base 264 2021E 2022E 2022E 719 2023E 105 2023E 31 © 2021 Hyperfine, Inc. 1: Total revenue for the quarter ended March 31, 2021 was approximately $0.3 million. This amount is preliminary, unaudited and may change, was prepared by management and is based on the most current information available to management. 1,562 2024E 643 2024E 2,848 2025E 1,661 2025E HYPERFINE#33Investment priorities. Imaging Sensing Guided Intervention © 2021 Hyperfine, Inc. Clinical and regulatory Commercialization globally Next generation and consumables product development Execute deep learning Al apps Regulatory and clinical trial execution Commercialization in US and Global Product development Interventional MRI, robotics, and consumables development 32 HYPERFINE#34Highly compelling investment characteristics. Large Market Poised for Disruption Recurring Revenue Business Model Massive Pipeline Opportunity Hyperfine Capitalized to Succeed Attractive Valuation Relative to Growth Massive TAM of over $23 billion for imaging with potential to take market share and expand the market category. Both companies could unlock huge markets individually but combined have the potential to build an ecosystem across the care continuum. Designed to be a recurring revenue business with annual recurring revenue of greater than $250MM projected by 2025 Product and applications pipeline has the potential to unlock markets with $50 billion in incremental addressable markets for sensing and guided intervention. Liminal Sciences has the potential to substantially change the way neuro care is delivered by providing non-invasive, real-time brain vitals to doctors that were previously inaccessible. ~$375MM¹ of cash to drive Hyperfine through its investment phase and to positive cash flow 10.7x 2023E revenues with projected revenue CAGR of 238% 2021 - 2025 versus comparables² at ~13 - 18x 2023E revenues with meaningfully slower growth CAGRs of ~30%+ © 2021 Hyperfine, Inc. 1: Assuming no redemptions. Comprised of $207.0 million from the SPAC trust fund, $126.1 million from PIPE investors and $65.8 million from Hyperfine/Liminal balance sheet (assumed cash on Hyperfine/Liminal balance sheet at closing of the transaction), less $24.2 million transaction expenses. 2: Based on company projections, public filings, analyst estimates and Capital IQ as of 07/06/21. 33 HYPERFINE#35HYPERFINE Thank you Come join us! Help us make the future. July 2021 O2021 Hyperfine, Inc. 18000 200kg/440lb MAX#36Proven team, clear mission, driven to succeed Dave Scott Chief Executive Officer Robert Glashow Acting Chief Financial Officer Ryan Silvestri Head of Product Engineering © 2021 Hyperfine, Inc. Dr. Khan Siddiqui Chief Strategy Officer & Chief Medical Officer Ruby Gill Head of Product Dr. David Rosenthal Chief Medical Officer, 4Catalyzer Mark Hughes Chief Operations Officer Rob Korn SVP Global Sales Brian Welch Sr. Director Clinical Science 35 Chris Ward Head of Marketing Dr. Eddie Knopp Sr. Medical Director Michael Poole Head of Advanced Development Neela Paykel General Counsel Kamyar Firouzi Chief Technology Officer, Liminal Elena Kaye Senior Scientist / Interventional Leader HYPERFINE#3799 issued patents and 285 pending applications Operates on the same amount of power as a coffee maker <1.6kW powered MRI system © 2021 Hyperfine, Inc. <50" diameter self-contained MRI system Noise cancelling technology to reduce interference MRI scanner on wheels 36 10000 AACQG Cht HYPERFINE HYPERFINE#38Competitive imaging Setting Imaging Use Cases Limitations Benefits © 2021 Hyperfine, Inc. Portable CT CereTom ED - Neuro ICU СТ, СТА, СТР Stroke Larger size - lonizing radiation Widely available and fast 37 Portable MRI Swoop ED - Neuro ICU T1, T2, FLAIR, DWI Stroke Ergonomics Reduces radiation exposure HYPERFINE#39Product Name Overview Use cases Features Notes Availability © 2021 Hyperfine, Inc. Medtronic - Polestar N10 0.12T (Odin) - Polestar N20 (Odin) - Polestar N30 (Odin) Does not require extensive renovation of the OR or restrictions of instruments Tumor resections with real-time imaging. Image fusion of pre-operative diagnostic scans (CT, MR, PET and fMRI) with intra- operative images Total anesthesia and operation times are prolonged - No longer sold N10: $960,000 GE Signa 0.5 T Only 15 systems built, discontinued due to complicated siting requirements - Minimally invasive procedures - Focused ultrasound of breast lesions - Biopsies - Integrated focused ultrasound into scanner table setup - 3D tracking system Concept promoted before RSNA '93, unclear if commercialized - No longer sold - Signa: up to $2M Philips Panorama 1T - Panorama 0.23T Open MRI for obese and claustrophobic patients - Thermal ablation of brain tumors - Biopsy procedures and kinematic joint studies Optional OptoGuide enables real-time needle tracking Eliminates $30k craniotomy; reduce hospital stay and patient morbidity No longer sold MAGNETOM Open 0.2T Siemens It can be disassembled into 3 pieces for installation w/out site construction Tumor resections "instant field off" function to shut off the magnetic field within seconds if there is a complication Priced below most states certificate of need limits - $900,000 UCLA: Dr. R. Lufkin - 38 Hitachi AIRIS 0.3T Accommodates obese, claustrophobia, and pediatric patients Minimally invasive pain therapy: spinal disc prolapses, back and neck pain or arthritis, puncture of haematomas Laser No longer sold Fonar Fonar 360° Dual-purpose: when it's not used for surgery, it can be used, as is, for Dx. Minimally invasive therapies: RF, chemotherapy, microwave, drugs Special moveable bed allows the patient to be positioned at any height and any angle Revenues from diagnostic scanning can subsidize surgical program Work in progress - IMRIS Ceiling-mounted scanner can move in/out of OR - Siemens MAGNETOM 1.5T MAGNETOM 3T DBS positioning - Drug-delivery Tumor resection Laser ablation - BrainLab Brain Suite SW nav partnership - Ceiling mounted to move between OR's Can be used for diagnostic imaging "IMRI to the patient" - $1.5+ M - 75 systems WW HYPERFINE